en

PRODUCT DETAIL

RINVOQ 30 mg tablety s predĺženým uvoľňovaním

Code 8489D
MA number EU/1/19/1404/009
Product Form: tbl plg 98 (2x49)x30 mg (blis.PVC/PE/PCTFE/Al)
MA Status: E - Valid centralised marketing authorisation
Type of procedure: EU
MAH, country: AbbVie Deutschland GmbH & Co. KG, Germany
Therapeutic Class: 59 - IMMUNOPRAEPARATA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 Immunosuppressants
L04A Immunosuppressants
L04AA Selective immunosuppressants
L04AA44 Upadacitinib
Shelf life: 24
Route of admin.: Oral use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 8(3) application - new active substance
MA issued: 16.12.2019
SmPC + PL: European Medicines Agency's database
Dokument: Rinvoq_Edukacna prirucka pre lekarov.pdf  
Dokument: Rinvoq_Karta pacienta.pdf  
Safety feature Yes
Data update: 10.10.2024
eu-flag.png sk-flag.png